The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms are actively being developed and will be launched soon.
27 May 2014
The final analysis of SPLENDOUR trial did not show improvement in overall survival in advanced Non-Small Lung Cancer
21 Oct 2018